Clinical Trials Logo

Stage IVC Salivary Gland Cancer clinical trials

View clinical trials related to Stage IVC Salivary Gland Cancer.

Filter by:

NCT ID: NCT00507767 Completed - Tongue Cancer Clinical Trials

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00126607 Terminated - Clinical trials for Recurrent Salivary Gland Cancer

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well trastuzumab works in treating patients with metastatic or recurrent salivary gland cancer. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them

NCT ID: NCT00114283 Completed - Tongue Cancer Clinical Trials

Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lapatinib ditosylate works in treating patients with metastatic or recurrent head and neck cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00096512 Completed - Tongue Cancer Clinical Trials

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It may also stop the growth of tumor cells by stopping blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with recurrent or metastatic head and neck cance

NCT ID: NCT00095628 Completed - Clinical trials for Stage IV Squamous Cell Carcinoma of the Hypopharynx

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Start date: January 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00068497 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Start date: August 2003
Phase: N/A
Study type: Interventional

This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for their growth

NCT ID: NCT00033618 Completed - Tongue Cancer Clinical Trials

Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck

Start date: November 2002
Phase: Phase 2
Study type: Interventional

Randomized phase II trial to study the effectiveness of ixabepilone in treating patients who have metastatic or recurrent head and neck cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die